Terms ending in 2029
Every in-force patent on Acceleron Pharma Inc.'s record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,988,973 | Activin-Actrii Antagonists and Uses for Increasing Red Blood Cell Levels In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 8,293,238 | GDF3 Antibodies and Related Methods In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 8,158,584 | Pharmaceutical Preparations Comprising an ALK1-FC Fusion Protein In force · High confidence | Ludwig Institute for Cancer Research Ltd. | In force | High confidence | |
| US 8,173,601 | Activin-Actriia Antagonists and Uses for Treating Multiple Myeloma In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 8,216,997 | Methods for Increasing Red Blood Cell Levels and Treating Anemia Using a Combination of GDF Traps and Erythropoietin Receptor Activators In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 8,361,957 | An Isolated GDF Trap Polypeptide In force · High confidence | Acceleron Pharma, Inc. | In force | High confidence | |
| US 8,703,927 | Isolated Nucleotide Sequences Encoding GDF Traps In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 9,439,945 | Isolated Nucleotide Sequences Encoding GDF Traps In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 9,505,813 | Use of GDF Traps to Treat Anemia In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 9,932,379 | Isolated Nucleotide Sequences Encoding GDF Traps In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | |
| 9 more term ends in 2029 · Pro | |||||
10 of 19 patents shown. Soonest term end first, then patent number.
Pro members see all 19.
18 of these are in force and held by Acceleron Pharma Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.